Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
<p>Abstract</p> <p>Introduction</p> <p>The aim of this study was to assess the cost-utility of palivizumab versus no prophylaxis in the prevention of respiratory syncytial virus infection among high-risk preterm infants.</p> <p>Methods</p> <p>We...
Main Authors: | Ravasio Roberto, Chirico Gaetano, Sbarigia Urbano |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2009-02-01
|
Series: | Italian Journal of Pediatrics |
Online Access: | http://www.ijponline.net/content/35/1/4 |
Similar Items
-
Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
by: Asunci&oacute;n Mej&iacute;as, et al.
Published: (2008-09-01) -
Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
by: M. Sanchez-Luna, et al.
Published: (2017-10-01) -
THE EFFICACY OF THE COSTS ON SEVERE RESPIRATORY SYNCYTIAL INFECTION PREVENTION WITH PALIVIZUMAB IN PRETERM INFANTS
by: A. V. Rudakova, et al.
Published: (2012-07-01) -
Mechanism of human respiratory syncytial virus (hRSV) resistance to palivizumab
by: Welsh, Sarah Helen
Published: (2009) -
Palivizumab prophylaxis of RSV infections in Bosnia and Herzegovina
by: Suada Heljic, et al.
Published: (2016-02-01)